Narrative review: The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies

Roger L. Williams, Darrell R. Abernethy, Leonard Bielory, Richard S. Blum, Nancy J. Braden, Karim A. Calis, David H. Campen, Stan N. Finkelstein, Thomas S. Foster, Mark L. Horn, Duane M. Kirking, Michael Murray, N. Lee Rucker, Joanne G. Schwartzberg, Alexander M M Shepherd, Colette F. Strnad, Dennis P. West, Edward Westrick, Stefan Schuber

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 includes a provision directing the Secretary of the U.S. Department of Health and Human Services to request that the U.S. Pharmacopeia (USP) develop a list of categories and classes (the USP Model Guidelines) that can be used by prescription drug plans in developing their formularies for the Part D prescription drug benefit. The Centers for Medicare & Medicaid Services (CMS) used the Model Guidelines and USP's related listing, termed the Formulary Key Drug Types, to evaluate prescription drug plan formularies submitted by prescription drug plan sponsors intending to provide the new Part D benefit. This article recounts how USP's all-volunteer Model Guidelines Expert Committee developed the USP Model Guidelines and Formulary Key Drug Types, working under a cooperative agreement with CMS in response to the Secretary's request. The Model Guidelines and Formulary Key Drug Types are updated annually to reflect advances in evidence-based medicine, thereby offering timely guidance to CMS and to prescription drug plans based on USP's demonstrated expertise in setting standards.

Original languageEnglish (US)
Pages (from-to)448-453
Number of pages6
JournalAnnals of Internal Medicine
Volume145
Issue number6
StatePublished - Sep 19 2006
Externally publishedYes

Fingerprint

Medicare Part D
Formularies
Pharmacopoeias
Prescription Drugs
Guidelines
Medication Therapy Management
Pharmaceutical Preparations
United States Dept. of Health and Human Services
Evidence-Based Medicine
Medicaid
Medicare
Volunteers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Williams, R. L., Abernethy, D. R., Bielory, L., Blum, R. S., Braden, N. J., Calis, K. A., ... Schuber, S. (2006). Narrative review: The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies. Annals of Internal Medicine, 145(6), 448-453.

Narrative review : The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies. / Williams, Roger L.; Abernethy, Darrell R.; Bielory, Leonard; Blum, Richard S.; Braden, Nancy J.; Calis, Karim A.; Campen, David H.; Finkelstein, Stan N.; Foster, Thomas S.; Horn, Mark L.; Kirking, Duane M.; Murray, Michael; Rucker, N. Lee; Schwartzberg, Joanne G.; Shepherd, Alexander M M; Strnad, Colette F.; West, Dennis P.; Westrick, Edward; Schuber, Stefan.

In: Annals of Internal Medicine, Vol. 145, No. 6, 19.09.2006, p. 448-453.

Research output: Contribution to journalArticle

Williams, RL, Abernethy, DR, Bielory, L, Blum, RS, Braden, NJ, Calis, KA, Campen, DH, Finkelstein, SN, Foster, TS, Horn, ML, Kirking, DM, Murray, M, Rucker, NL, Schwartzberg, JG, Shepherd, AMM, Strnad, CF, West, DP, Westrick, E & Schuber, S 2006, 'Narrative review: The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies', Annals of Internal Medicine, vol. 145, no. 6, pp. 448-453.
Williams RL, Abernethy DR, Bielory L, Blum RS, Braden NJ, Calis KA et al. Narrative review: The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies. Annals of Internal Medicine. 2006 Sep 19;145(6):448-453.
Williams, Roger L. ; Abernethy, Darrell R. ; Bielory, Leonard ; Blum, Richard S. ; Braden, Nancy J. ; Calis, Karim A. ; Campen, David H. ; Finkelstein, Stan N. ; Foster, Thomas S. ; Horn, Mark L. ; Kirking, Duane M. ; Murray, Michael ; Rucker, N. Lee ; Schwartzberg, Joanne G. ; Shepherd, Alexander M M ; Strnad, Colette F. ; West, Dennis P. ; Westrick, Edward ; Schuber, Stefan. / Narrative review : The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies. In: Annals of Internal Medicine. 2006 ; Vol. 145, No. 6. pp. 448-453.
@article{ee0cb3a87de942be86ca2a2326684133,
title = "Narrative review: The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies",
abstract = "The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 includes a provision directing the Secretary of the U.S. Department of Health and Human Services to request that the U.S. Pharmacopeia (USP) develop a list of categories and classes (the USP Model Guidelines) that can be used by prescription drug plans in developing their formularies for the Part D prescription drug benefit. The Centers for Medicare & Medicaid Services (CMS) used the Model Guidelines and USP's related listing, termed the Formulary Key Drug Types, to evaluate prescription drug plan formularies submitted by prescription drug plan sponsors intending to provide the new Part D benefit. This article recounts how USP's all-volunteer Model Guidelines Expert Committee developed the USP Model Guidelines and Formulary Key Drug Types, working under a cooperative agreement with CMS in response to the Secretary's request. The Model Guidelines and Formulary Key Drug Types are updated annually to reflect advances in evidence-based medicine, thereby offering timely guidance to CMS and to prescription drug plans based on USP's demonstrated expertise in setting standards.",
author = "Williams, {Roger L.} and Abernethy, {Darrell R.} and Leonard Bielory and Blum, {Richard S.} and Braden, {Nancy J.} and Calis, {Karim A.} and Campen, {David H.} and Finkelstein, {Stan N.} and Foster, {Thomas S.} and Horn, {Mark L.} and Kirking, {Duane M.} and Michael Murray and Rucker, {N. Lee} and Schwartzberg, {Joanne G.} and Shepherd, {Alexander M M} and Strnad, {Colette F.} and West, {Dennis P.} and Edward Westrick and Stefan Schuber",
year = "2006",
month = "9",
day = "19",
language = "English (US)",
volume = "145",
pages = "448--453",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Narrative review

T2 - The U.S. Pharmacopeia and Model Guidelines for medicare Part D formularies

AU - Williams, Roger L.

AU - Abernethy, Darrell R.

AU - Bielory, Leonard

AU - Blum, Richard S.

AU - Braden, Nancy J.

AU - Calis, Karim A.

AU - Campen, David H.

AU - Finkelstein, Stan N.

AU - Foster, Thomas S.

AU - Horn, Mark L.

AU - Kirking, Duane M.

AU - Murray, Michael

AU - Rucker, N. Lee

AU - Schwartzberg, Joanne G.

AU - Shepherd, Alexander M M

AU - Strnad, Colette F.

AU - West, Dennis P.

AU - Westrick, Edward

AU - Schuber, Stefan

PY - 2006/9/19

Y1 - 2006/9/19

N2 - The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 includes a provision directing the Secretary of the U.S. Department of Health and Human Services to request that the U.S. Pharmacopeia (USP) develop a list of categories and classes (the USP Model Guidelines) that can be used by prescription drug plans in developing their formularies for the Part D prescription drug benefit. The Centers for Medicare & Medicaid Services (CMS) used the Model Guidelines and USP's related listing, termed the Formulary Key Drug Types, to evaluate prescription drug plan formularies submitted by prescription drug plan sponsors intending to provide the new Part D benefit. This article recounts how USP's all-volunteer Model Guidelines Expert Committee developed the USP Model Guidelines and Formulary Key Drug Types, working under a cooperative agreement with CMS in response to the Secretary's request. The Model Guidelines and Formulary Key Drug Types are updated annually to reflect advances in evidence-based medicine, thereby offering timely guidance to CMS and to prescription drug plans based on USP's demonstrated expertise in setting standards.

AB - The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 includes a provision directing the Secretary of the U.S. Department of Health and Human Services to request that the U.S. Pharmacopeia (USP) develop a list of categories and classes (the USP Model Guidelines) that can be used by prescription drug plans in developing their formularies for the Part D prescription drug benefit. The Centers for Medicare & Medicaid Services (CMS) used the Model Guidelines and USP's related listing, termed the Formulary Key Drug Types, to evaluate prescription drug plan formularies submitted by prescription drug plan sponsors intending to provide the new Part D benefit. This article recounts how USP's all-volunteer Model Guidelines Expert Committee developed the USP Model Guidelines and Formulary Key Drug Types, working under a cooperative agreement with CMS in response to the Secretary's request. The Model Guidelines and Formulary Key Drug Types are updated annually to reflect advances in evidence-based medicine, thereby offering timely guidance to CMS and to prescription drug plans based on USP's demonstrated expertise in setting standards.

UR - http://www.scopus.com/inward/record.url?scp=33749163672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749163672&partnerID=8YFLogxK

M3 - Article

C2 - 16983132

AN - SCOPUS:33749163672

VL - 145

SP - 448

EP - 453

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -